Findings

What do systematic reviews say?

3 questions · 3 findings · 2 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 33.3%GRADE not reported 0 · 0%Very low 0 · 0%Low 2 · 66.7%Moderate 0 · 0%High 0 · 0%

Radioembolisation plus sorafenib vs sorafenib monotherapy

All‐cause mortality at 1 year · people with hepatocellular carcinoma

The review found no eligible studies for this question.

1 finding from 1 review

Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

All‐cause mortality a. Intervention vs placebo [30 weeks to 4.75 years] b. Intervention vs insulin [4.75 years to 10.0 years] · participants with type 2 diabetes mellitus

The intervention showed no clear difference in all‐cause mortality a. Intervention vs placebo [30 weeks to 4.75… (low certainty).

1 finding from 1 review

Sulphonylurea monotherapy for patients with type 2 diabetes mellitus 2013 · Cochrane Headline outcomes only
RR 1.46 [0.87, 2.45]
2 studies · 553 participants
Low

Intervention not reported

All‐cause mortality a. Intervention vs metformin [a. 24 weeks to 4 years] b. Intervention vs thiazolidinediones [b. 24 weeks to 4 years] c. Intervention vs insulin [c. 9 months to 10 years] d. Intervention vs incretin‐based control [d. 52 weeks to... · participants with type 2 diabetes mellitus

The intervention showed no clear difference in all‐cause mortality a. Intervention vs metformin [a. 24 weeks to 4… (low certainty).

1 finding from 1 review

Sulphonylurea monotherapy for patients with type 2 diabetes mellitus 2013 · Cochrane Headline outcomes only
RR 0.98 [0.61, 1.58]
6 studies · 3528 participants
Low